Axonex Intelligence and Synergy Technology Group Form Joint Venture to Accelerate Digital Twin and Drone Flight Control Expansion ACN Newswire

Axonex Intelligence and Synergy Technology Group Form Joint Venture to Accelerate Digital Twin and Drone Flight Control Expansion

HONG KONG, Mar 12, 2026 - (ACN Newswire via SeaPRwire.com) – Mint Incorporation Limited (“Mint” or the “Group”, NASDAQ: MIMI), a Hong Kong-based company with a new strategic focus on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, today announced that its wholly-owned subsidiary, Axonex Intelligence Limited (“AXONEX”) has entered into a joint venture agreement (the “JV Agreement”) with Synergy Technology Group Limited (“STG”) to establish Axonex Automation Limited (“JV company”), a new Hong Kong-based joint venture company focused on commercializing advanced digital twin and drone flight control technologies in Hong Kong and selected overseas markets.Under the JV Agreement, AXONEX will hold an 80% equity interest in Axonex Automation Limited, while STG will hold the remaining 20%. The joint venture will combine AXONEX’s operational resources and international business capabilities with STG’s proven technology in digital twins and drone flight control systems to drive scalable deployment in sectors such as infrastructure inspection, utilities, smart cities, and industrial operations.AXONEX has committed to provide up to HK$ 20,000,000 of capital to the joint venture in stages, subject to the achievement of defined business and technical milestones set out in the agreement. The funding will be released through four tranches over an expected 12–24-month period.STG will contribute technology, intellectual property, know-how, and ongoing technical support to the JV company, initially via a license of its core digital twin and drone flight control platforms, the “Zhishan No-Code Digital Twin Universal Platform and related drone inspection technologies” to Axonex Automation Limited.Mr. Damian Chan, Chairman of the Board and Chief Executive Officer of Mint stated: “This joint venture creates a focused vehicle to bring next-generation digital twin and autonomous drone capabilities from concept to commercial reality across Hong Kong and key overseas markets.”A representative of Synergy Technology Group Limited added: “Our collaboration with AXONEX will accelerate the real-world adoption of our digital twin and drone flight control technologies in critical infrastructure, smart city, and industrial applications, leveraging Hong Kong as a launchpad for global expansion.”Photo CaptionMr. Damian Chan, Chairman of the Board and Chief Executive Officer of Mint (Right) and Mr. Jiang Xiaotong, founder of STG (Left) signed the JV to establish Axonex Automation Limited focused on commercializing advanced digital twin and drone flight control technologies in Hong Kong and selected overseas markets.About Mint Incorporation LimitedMint Incorporation Limited (NASDAQ: MIMI), a Hong-Kong based enterprise listed on NASDAQ, specializes in artificial intelligence (AI), robotics, and interior design. Through its subsidiary Axonex Intelligence Limited, the company delivers intelligent robotics and facility management solutions to enterprises, real estate, shopping centers, government agencies, and more. Mint also operates Matter International Limited, providing professional interior design and renovation services. With a focus on innovation and practical applications, Mint is committed to enhancing efficiency, safety, and quality of life across industries.About Synergy Technology Group LimitedSynergy Technology Group Limited is a Hong Kong-based technology company specializing in advanced digital twin solutions and drone flight control systems, with applications across infrastructure monitoring, utilities, and smart city ecosystems. Founded by Jiang Xiaotong, an Associate Professor at Southeast University, Synergy Technology Group Limited operates under a license from Nanjing Zhishan Intelligent Technology Research Institute Co., Ltd for the “Zhishan No-Code Digital Twin Universal Platform and related drone inspection technologies”.Forward-Looking StatementsCertain statements in this release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results disclosed in the Company’s filings with the SEC. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Axonex Intelligence与互惠智科有限公司共同成立合资企业 ACN Newswire

Axonex Intelligence与互惠智科有限公司共同成立合资企业

香港, 2026年3月12日 - (亚太商讯 via SeaPRwire.com) - Mint Incorporation Limited("Mint"或"集团",纳斯达克股票代码:MIMI)─ 一家专注于人工智能与机械人技术,同时提供商业室内设计及装修服务的香港本地企业,今日欣然宣布,其全资子公司 Axonex Intelligence Limited ("AXONEX")已与互惠智科有限公司("互惠智科")订立合资协议,共同成立Axonex Automation Limited("合资企业"),一家总部位于香港,专注香港及特定海外市场将先进的数字孪生及无人机飞行控制技术商业化的新合资企业。根据合资协议,AXONEX将持有Axonex Automation Limited 80%的股权,而互惠智科将持有其余20%。这合资协议将结合AXONEX的营运资源与国际业务能力,及互惠智科在数字孪生与无人机飞行控制系统领域的成熟技术,以推动在基础设施检测、公用事业、智慧城市及工业营运等领域的可规模化部署。AXONEX 已承诺按阶段向合资企业投入最高达20,000,000港元的资金,具体金额将按协议所订明的业务及技术里程碑的达成情况而拟定。相关资金预计将于12至24个月期间内分四期拨付。互惠智科将向合资企业提供技术、知识产权、专业技能及持续的技术支援,初期将向Axonex Automation Limited授权其"止善零代码数字孪生通用平台"及无人机巡检相关业务。Mint董事会主席兼行政总裁陈海龙先生表示:"是次与互惠智科的合资协议将创建一个平台,专注将新一代数字孪生及自动驾驶无人机技术,在香港及多个重要海外市场从概念阶段推向商业应用。"互惠智科有限公司的代表补充道:"与AXONEX的合作将加速我们的数字孪生及无人机飞行控制技术在关键基础设施、智慧城市及工业应用领域的实际落地,并以香港为起点,实现全球业务拓展。"图片说明Mint董事会主席兼行政总裁陈海龙先生(右)与互惠智科创办人姜晓彤先生(左)签署合资协议,共同成立Axonex Automation Limited,专注香港及特定海外市场将先进的数字孪生及无人机飞行控制技术商业化。有关Mint Incorporation LimitedMint Incorporation Limited(纳斯达克股票代码:MIMI)是一家于纳斯达克上市的香港本地企业,专注于人工智能、机械人技术及室内设计领域。透过其子公司 Axonex Intelligence Limited,公司为企业、地产、商场、政府机构等提供智能机械人与设施管理解决方案。Mint 同时营运 Matter International Limited,提供专业室内设计与装修服务。秉持创新与实际应用并重的理念,Mint 致力于提升各行各业的效率、安全性与生活质素。有关互惠智科有限公司互惠智科有限公司是一家总部位于香港的科技企业,专门提供先进的数字孪生解决方案及无人机飞行控制系统,其应用领域涵盖基础设施监测、公共设施及智慧城市生态系统。由东南大学副教授姜晓彤创立,互惠智科有限公司获南京止善智能科技研究院有限公司所授予的许可,营运"止善零代码数字孪生通用平台"及"无人机巡检"相关业务。前瞻性陈述本新闻稿中的某些陈述属于前瞻性陈述。这些前瞻性陈述涉及已知和未知的风险和不确定性,并基于公司对可能影响其财务状况、营运成果、业务策略和财务需求的未来事件的目前期望和预测。投资者可通过"大约"、 "相信 "、 "希望 "、 "期望 "、 "预期 "、 "估计 "、"项目 "、 "打算 "、 "计划 "、 "将 "、 "将会 "、 "应该"、 "可能"或其他类似的词语或短语识别这些前瞻性陈述。公司不承担更新或修订任何前瞻性陈述以反映随后发生的事件或情况,或其期望的变化的公开义务,除非法律要求。尽管公司认为这些前瞻性陈述所表达的期望是合理的,但无法保证这些期望将会被证实正确,并提醒投资者实际结果可能与预期结果有显著差异,并鼓励投资者查阅可能影响其未来结果的其他因素,这些因素披露在公司向证券交易委员会提交的文件中。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
NEC and The University of Tokyo calculate carbon accumulation rates in Malaysian national park with a 9.4% margin of error JCN Newswire

NEC and The University of Tokyo calculate carbon accumulation rates in Malaysian national park with a 9.4% margin of error

The University of Tokyo’s carbon cycle assessment model, VISIT, and NEC’s data assimilation technology calculate decarbonization effect in forests with greater efficiency and accuracy than conventional methodsTOKYO, Mar 12, 2026 - (JCN Newswire via SeaPRwire.com) - The University of Tokyo’s Graduate School of Agricultural and Life Sciences, Faculty of Agriculture, and NEC have calculated carbon accumulation rates for Lambir Hills National Park in Malaysia based on observed removals data for greenhouse gases (GHG) utilizing the university’s VISIT (Vegetation Integrated SImulator for Trace gases) terrestrial ecosystem model.NEC’s data assimilation technology (patent pending) was used to correct data errors, and observed data was compared with simulated data in order to calculate carbon accumulation rates with a high degree of accuracy, achieving a daily margin of error of 9.4%.BackgroundNEC is promoting initiatives to quantify GHG removals in forests across Southeast Asia and to develop carbon credits in the forest sector. As part of these efforts, NEC has been conducting joint research with the Graduate School of Agricultural and Life Sciences at The University of Tokyo, which developed the VISIT model, an ecosystem model with strengths estimating carbon stocks and fluxes (*1) in forests in the Asian region.The VISIT model estimates carbon stocks and fluxes based on forest vegetation, soil, and meteorological data. By combining VISIT with NEC’s data assimilation technology, exceptionally high-precision estimation of forest carbon accumulation rates has become possible.Data assimilation technology is a computational method that improves model accuracy by adjusting model parameters based on differences between model outputs and observed data. NEC’s data assimilation technology is designed to enhance the accuracy of carbon flux estimations for the future by linking VISIT with image data obtained from satellite-mounted sensors. A patent application has been filed by NEC for this technology.Key features of the VISIT modelThe VISIT model assesses carbon cycles in terrestrial ecosystems. In addition to enabling estimation of carbon stocks and fluxes using vegetation, soil, and meteorological data, the model can also assess the impacts of land-use changes and climate change. VISIT is particularly well suited for improving accuracy based on observed data and is regarded as highly reliable compared with other similar models.Furthermore, the VISIT model is applicable to forests across Asia, including Japan. The methodologies recommended by the Verified Carbon Standard (VCS), the world’s largest voluntary carbon crediting program, primarily reference models developed for Europe and North America and have not specified models tailored to Asian regions (*2). This joint research utilizing the VISIT model is expected to make important contributions to the advancement of forest carbon credit development in Asia.Key features of data assimilationData assimilation is a computational method that improves the accuracy of model estimation by correcting model parameters based on differences between model outputs and observed data. The NEC data assimilation technology used in this joint research has the potential, in the future, to enhance the accuracy of carbon flux estimation by linking the VISIT model with satellite-mounted hyperspectral sensors. A patent application has been filed by NEC for this technology.Currently, the application of data assimilation technology to observational models in the forestry field is not widespread. By applying this technology to the VISIT model, more efficient and highly accurate data collection in forest environments becomes possible, contributing to the advancement of forest conservation initiatives.Building on the findings obtained through this joint research, NEC will accelerate its initiatives in natural capital accounting and carbon credit development.(1) The amount of carbon dioxide absorbed and emitted between forests and the atmosphere.(2) Source: Verra, a nonprofit organization that operates standards in environmental and social markets. About NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.For more information, please visit https://www.nec.com, Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More

伯利兹启动世界卫生组织SPECS 2030倡议,推进国家眼健康事业

(SeaPRwire) - 伯利兹城,伯利兹,2026年3月11日——伯利兹通过正式启动世界卫生组织(WHO)SPECS 2030倡议,在确保该国每个人都能获得优质、负担得起的眼部护理方面迈出了重要一步。 此次全国启动和规划研讨会汇集了来自卫生与健康部(MOHW)、外交、外贸、教育、文化、科学和技术部、Belize Council for the Visually Impaired (BCVI)、OneSight EssilorLuxottica Foundation、世界卫生组织(WHO)和Pan American Health Organization (PAHO)的代表。与会者齐聚一堂,评估伯利兹眼部健康服务的现状,找出差距,并规划出明确的前进道路。 “随着世界卫生组织(WHO)SPECS 2030倡议的启动,伯利兹在确保每位公民都能获得优质眼部护理的承诺上取得了进展。可预防的视力障碍不应限制儿童的学习、个人的工作能力或生活质量。通过采纳该倡议,我们正在加强我们国家对一个更强大、更公平、不让任何人掉队的卫生系统的愿景,”卫生与健康部长Hon. Kevin Bernard表示。 世界卫生组织(WHO)的SPECS 2030倡议为各国提供了一个结构化的方法,以在五个领域加强屈光不正服务: 服务 — 改善屈光服务的可及性人员 — 建设提供屈光服务的人员能力教育 — 促进公众对眼部健康的认识成本 — 降低眼镜和服务的成本监测 — 加强数据收集和研究 对于伯利兹而言,该倡议在国家层面转化为三个明确的优先事项。首先,召集所有相关的眼部健康利益攸关方——包括公共和私营部门——就国家优先事项和关键行动领域达成一致。其次,制定一个可衡量目标的SPECS 2030整合计划,并将其嵌入伯利兹更广泛的健康和眼部护理战略中。第三,建立一个监测和评估框架,以跟踪进展,定期审查数据,并随着时间的推移改进服务。 “伯利兹正在展示像世界卫生组织(WHO)SPECS 2030这样的全球框架如何转化为实际的、国家主导的行动。OneSight EssilorLuxottica Foundation在此项工作中的作用是支持技术实施——从加强屈光服务到建设当地能力和改进服务交付模式。我们很荣幸能与伯利兹站在一起,共同推进一个更综合、更易获得的眼部护理系统,”OneSight EssilorLuxottica Foundation拉丁美洲负责人Daniele Cangemi表示。 进展将根据一套明确的指标进行衡量,并通过世界卫生组织(WHO)全球状况报告每三到五年报告一次。这些指标包括学校眼部健康计划早期检测的覆盖范围、公共卫生系统内屈光服务的可用性、眼部护理人员的规模和范围,以及通过健康保险或其他财政保护机制覆盖成本的程度。在影响层面,伯利兹将通过基于人口的调查和卫生系统数据跟踪有效的白内障手术覆盖率和有效的屈光不正覆盖率。 “外交、外贸、教育、文化、科学和技术部欢迎Belize Council for the Visually Impaired (BCVI)和卫生与健康部与Pan American Health Organization (PAHO)和OneSight EssilorLuxottica Foundation合作推出的世界卫生组织(WHO)SPECS 2030倡议。我们致力于加强与Belize Council for the Visually Impaired (BCVI)和卫生与健康部的伙伴关系和合作,共同努力预防可避免的失明,并通过现有的初级保健和康复计划为盲童扩大支持服务。本部门祝贺并赞扬Belize Council for the Visually Impaired (BCVI)对伯利兹视障社区的持续奉献和承诺,”外交、外贸、教育、文化、科学和技术部长Hon. Francis Fonseca评论道。 Belize Council for the Visually Impaired (BCVI)将与卫生与健康部、OneSight EssilorLuxottica Foundation以及该倡议的国家和国际合作伙伴合作,领导协调和后续工作,以确保研讨会上作出的承诺转化为实地的有意义进展。 SPECS 2030的启动反映了伯利兹对全民健康覆盖的承诺,以及对一个未来,即没有伯利兹人会因为本可纠正的视力问题而失去学习、工作或茁壮成长的能力。 关于OneSight EssilorLuxottica FoundationOneSight EssilorLuxottica Foundation是一个注册慈善组织,致力于在一代人时间内消除未矫正的视力不良问题。作为EssilorLuxottica对普及视力护理承诺的一部分,该基金会致力于为全球服务不足社区的数百万人扩大视力护理的可及性。它也是世界卫生组织(WHO)SPECS 2030倡议的全球合作伙伴,该倡议专注于屈光不正、近视预防和改善低资源环境下的视力护理可及性。 了解更多信息,请访问:onesight.essilorluxottica.com 关于Belize Council for the Visually Impaired (BCVI)Belize Council for the Visually Impaired (BCVI)是一个全国性的非营利组织,致力于预防失明和提供全面的眼部护理服务。Belize Council for the Visually Impaired (BCVI)成立于1981年,与卫生与健康部合作,在全国范围内提供可及、负担得起且高质量的眼部护理服务。通过诊所和外展计划网络,Belize Council for the Visually Impaired (BCVI)提供包括眼科检查、屈光不正服务、眼部疾病治疗以及对不可逆转失明者的康复支持等服务。 特别倡议侧重于儿童、糖尿病患者和服务不足的社区,确保没有伯利兹人在获得基本眼部护理和独立生活支持方面被遗漏。Belize Council for the Visually Impaired (BCVI)与地方和国际合作伙伴合作,以加强伯利兹的眼部健康系统,并促进所有人公平获得服务。欲了解更多信息,请访问:www.bcvi.org 欲了解更多信息,请联系: Belize Council for the Visually Impaired (BCVI)Carla Ayres Musa,执行董事cmusa.bcvi@gmail.comOneSight EssilorLuxottica FoundationTamana Mulchand,传播与意识经理tamana.mulchand@essilor.com本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More

Mainz Biomed 宣布任命 Robert Liscouski 为董事会主席

(SeaPRwire) - 公司同时宣布新名称:Quantum Cyber 及纳斯达克股票代码变更加利福尼亚州伯克利,2026年3月11日 -- Mainz Biomed N.V. (NASDAQ: MYNZ),一家专注于癌症早期检测的分子遗传学诊断公司,今日宣布任命罗伯特·P·利斯卡斯基为其董事会主席。此外,公司宣布计划更名为Quantum Cyber,并将其纳斯达克股票代码变更为QUCY,自2026年3月12日起生效。利斯卡斯基先生的正式选举以及公司名称变更将在计划于2026年4月举行的公司特别股东大会上生效。公司将于2026年3月12日开始以Quantum Cyber的名义开展业务,并以代码QUCY进行交易。 利斯卡斯基先生是CNBC、CNN、BBC、Fox News及其他商业和安全媒体在国土安全、恐怖主义和网络安全议题上的常任评论员,并曾就国土安全问题出席国会听证。利斯卡斯基先生获得哈佛大学约翰·F·肯尼迪政府学院的公共管理硕士学位。 政府技术倡议利斯卡斯基先生由乔治·W·布什总统任命,在2003年911袭击后美国国土安全部成立时,担任首任基础设施保护助理部长。在任期内,利斯卡斯基先生负责基础设施保护办公室的设计、开发、实施和管理,包括整合来自其他政府机构(如FBI、DoD、General Services Administration、Department of Energy和Department of Commerce)的各个单位,并创建了国家网络安全部门。利斯卡斯基先生的基础性努力促成了今天的网络安全和基础设施安全局(CISA)的建立。 网络安全与人工智能创新利斯卡斯基先生最近曾担任Quantum Computing Inc.的联合创始人、首席执行官兼董事长,该公司是一家创新的集成光子学公司,制造易于获取且价格合理的量子机器。他的技术领导力延伸至人工智能和高性能计算领域。作为Fog Data Sciences, LLC的联合创始人,他在开发利用人工智能和先进计算能力的地理定位情报解决方案方面发挥了关键作用。这些解决方案满足了执法部门和美国安全与情报界的关键需求,将尖端技术应用于复杂的安全挑战。在The Coca-Cola Company,利斯卡斯基先生曾担任信息保障总监,负责评估、设计和实施公司的信息安全计划。 公司此前已宣布,打算继续专注于其在美国的胰腺癌筛查业务的发展,并评估出售其结直肠癌筛查资产的机会,同时逐步结束其德国子公司。公司在所有这些倡议上持续取得进展。 现任董事会主席David Lazar评论道:“Robert是一位经验丰富的全球高管,一位久经考验的技术领导者和安全专家,拥有超过35年的公共和私营部门经验,这使他成为我们的完美人选。他的职业生涯以对高科技倡议、网络安全和关键基础设施保护的重大贡献为标志,所有这些都与我们的长期计划完美契合。Robert的高科技领导经验包括担任Quantum Computing Inc. (Nasdaq: QUBT)的联合创始人、董事长和前首席执行官,在该公司他引领了尖端量子计算技术的开发。在他的领导下,该公司成为量子计算市场上第一家纯业务的上市公司,专注于纳米光子硬件,以帮助彻底改变计算的未来。” 前瞻性声明本新闻稿中的某些陈述构成1995年《私人证券诉讼改革法案》“安全港”条款所定义的“前瞻性陈述”。前瞻性陈述可以通过使用诸如“预期”、“相信”、“期望”、“估计”、“计划”、“展望”、“项目”等词语以及其他预测或指示未来事件或趋势或非历史事实陈述的类似表达来识别。这些前瞻性陈述反映了对现有信息的当前分析,并受到各种风险和不确定性的影响。因此,在依赖前瞻性陈述时必须谨慎行事。由于已知和未知的风险,实际结果可能与公司的预期或预测存在重大差异。除其他外,以下因素可能导致实际结果与这些前瞻性陈述中描述的结果存在重大差异:(i) 未能达到预期的开发及相关目标;(ii) 适用法律或法规的变化;(iii) 无法成功推进我们的新倡议;以及 (iv) 本文所述的其他风险和不确定性,以及公司在美国证券交易委员会(“SEC”)提交的其他报告和其他公开文件中不时讨论的风险和不确定性。有关这些及其他可能影响公司预期和预测的因素的更多信息,可在其向SEC提交的初始文件中找到,包括其于2025年3月31日提交的20-F表格年度报告和于2025年9月26日提交的6-K表格中期报告。公司的SEC文件可在SEC网站 www.sec.gov 上公开获取。我们在本新闻稿中作出的任何前瞻性陈述均仅基于Mainz Biomed目前可获得的信息,且仅代表其发表之日的观点。Mainz Biomed不承担任何义务公开更新任何前瞻性陈述,无论是书面还是口头的,无论是由于新信息、未来进展或其他原因,除非法律要求。 投资者垂询:Andrew J. Barwicki投资者关系电话:516-662-9461电子邮件: andrew@barwicki.com本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More

开心控股宣布股份合并

(SeaPRwire) - 北京,2026年3月11日讯 -- 开心控股(“开心”或“公司”)(纳斯达克股票代码:KXIN)宣布,其将对每股面值为1.35美元的普通股进行股份合并,合并比例为15比1,合并后每股面值为20.25美元,于2026年3月13日生效(“股份合并”)。公司的A类普通股预计将于2026年3月13日市场开盘时开始按合并后的基准进行交易。在2026年3月13日市场开盘时,公司的A类普通股将继续在纳斯达克资本市场交易,股票代码为“KXIN”,新的CUSIP编号为G5223X175。 由于股份合并,公司每十五(15)股普通股将自动合并为一股普通股。未行使认股权证和其他未行使股权将进行相应调整,以反映股份合并情况。股份合并不会发行零碎股份,如果股东在股份合并中有权获得零碎股份,该股东将获得的股份数量将向上取整为一股普通股,以代替因股份合并而产生的零碎股份。 公司的过户登记代理人Transhare Corporation,同时也担任股份合并的交换代理人,将向持有股票证书的登记股东发送有关将其旧证书换成新证书的指示(如果他们希望这样做)。通过经纪账户或“名义持有”方式持有股份的股东无需采取行动来进行股份交换。 关于开心控股 开心控股是一家在开曼群岛注册的控股公司,在中国汽车行业开展业务。 安全港声明 本公告可能包含前瞻性陈述。这些陈述是根据1995年美国《私人证券诉讼改革法案》中的“安全港”条款作出的。这些前瞻性陈述可以通过“将”、“预期”、“预计”、“未来”、“打算”、“计划”、“相信”、“估计”或其他类似表述来识别。并非历史事实的陈述,包括有关开心的信念和预期的陈述,均为前瞻性陈述。前瞻性陈述涉及固有风险和不确定性。许多因素可能导致实际结果与任何前瞻性陈述中包含的结果存在重大差异,包括但不限于以下因素:我们的目标和战略;我们未来的业务发展、财务状况和经营成果;我们对服务需求和市场接受度的预期;我们对与汽车经销商保持和加强关系的预期;我们提升用户体验、基础设施和服务产品的计划;中国行业内的竞争;以及与我们行业相关的政府政策和法规。有关这些及其他风险的更多信息包含在我们向美国证券交易委员会提交的其他文件中。本公告及附件中提供的所有信息均截至本公告发布之日,开心不承担更新任何前瞻性陈述的义务,除非适用法律要求。 如需更多信息,请联系: 开心控股 投资者关系 邮箱:ir@kaixin.com本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More

WANPY® XIAOJINDUN:中国首个通过SGS中-欧-美-日出口标准全面检测的宠物主粮产品线

(SeaPRwire) - 纽约,2026年3月11日——全球领先的独立检测认证机构SGS已针对WANPY®的高端XIAOJINDUN主食系列发布了一份具有里程碑意义的特别报告。这个中国宠物食品品牌主动将所有XIAOJINDUN产品提交检测,以符合中国、美国、欧盟和日本的法定出口标准,每一批次都全部通过了所有测试。所有批次均满足核心质量与安全指标的严格要求:原材料安全、微生物控制、农药和兽药残留限量、添加剂使用以及营养标签合规性。这标志着中国宠物主食品牌首次通过独立的逐批检测,一次性通过全球四大顶级监管市场的出口门槛。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Yuexiu REIT Maintains Operational Resilience, Revenue Exceeds RMB1.8 Billion in 2025 ACN Newswire

Yuexiu REIT Maintains Operational Resilience, Revenue Exceeds RMB1.8 Billion in 2025

HONG KONG, Mar 11, 2026 - (ACN Newswire via SeaPRwire.com) – Yuexiu Real Estate Investment Trust ("Yuexiu REIT", together with Yuexiu REIT Asset Management Limited, collectively known as the “REIT”; stock code: 405) announced its annual results for the year ended 31 December 2025.Yuexiu REIT Management Team: Chairman and Non-Executive Director Mr. JIANG Guoxiong (center), Executive Director and Chief Executive Officer Ms. OU Haijing (left), and Chief Financial Officer Mr. KWAN Chi Fai (right)2025 Annual Results Highlights: - Overall operation remained resilient, with total revenue of RMB1,856 million (2024: RMB2,032 million).- The average financing cost was 3.61%, a three-year low; the average interest payment rate was 3.77%, representing a year-on-year decrease of 76 basis points. Excluding exchange loss, the financing expenses decreased by approximately RMB152 million year-on-year.- As at 31 December 2025, the overall occupancy rate of the properties was 82.1% (2024: 84.5%).- Optimised the asset portfolio by disposing of a 50% interest in Yuexiu Financial Tower in Q4 2025, realising cash proceeds of approximately RMB5.3 billion to enhance financial flexibility. Yuexiu REIT maintained its "investment-grade" rating from both Standard & Poor's and Fitch, with the outlook upgraded to "stable".- The final distribution to the Unitholders for the period will be approximately RMB0.0189, equivalent to HK$0.0214. Distribution per Unit for the year will be approximately RMB0.0522, equivalent to HK$0.0580. Distribution yield is 6.74% per Unit for the year.- To maintain the REIT’s financial flexibility, the distribution ratio for the period from 1 July 2025 to 31 December 2025 has been adjusted to 90%, resulting in an overall full-year distribution ratio of approximately 96%.Guangzhou International Finance Center (GZIFC):- Operating revenue of the GZIFC complex was RMB984 million, accounting for 53.0% of the REIT’s total revenue.- The office building of GZIFC introduced two Fortune Global 500 companies; the occupancy rate was 80.9%.- GZIFC Shopping Mall introduced China Duty Free Group (CDFG), the first and currently the only downtown duty-free store in Guangzhou, achieving a renewal rate of 89% for the year, and an occupancy rate of 95.5% at the end of the period.- Four Seasons Hotel Guangzhou's average room rate increased by 5.8% year-on-year. Ascott Serviced Apartments GZIFC achieved an average occupancy rate of 91.5%, up 1 percentage point year-on-year, with revenue reaching a record high for the period.Proactive Management of Financing Risk and Effective Stabilisation of Financing Cost- With regard to the short-term loan of RMB530 million, the 5-year syndicated loan of HK$2.1 billion, and the remaining HK$2.1 billion of the 3-year syndicated loan of HK$3.8 billion, all due in 2025, the Manager in 2025 renewed the short-term loan of RMB530 million, obtained offshore loan of RMB1.7 billion, issued dim sum bonds of RMB1 billion, and obtained an offshore syndicated loan package equivalent to HK$2.1 billion (a sustainability-linked loan), for the refinancing of the maturing loans so as to ensure effective monitor on the liquidity risk.- A total of approximately RMB4.68 billion in loans were obtained in 2025 to partially refinance offshore HKD floating rate loans, taking advantage of the relatively low-cost of RMB financing to proactively adjust the financing structure. At the end of 2025, the financing interest rate exposure of Yuexiu REIT was approximately 10%, narrowed by 16 percentage points from 26% at the beginning of the year; the average financing cost was 3.61%, a three-year low, representing a decrease of 55 basis points from 4.16% at the beginning of the year; the average interest payment rate for the full year of 2025 was 3.77%, representing a year-on-year decrease of 76 basis points. Excluding the exchange loss, the finance expenses were approximately RMB773 million, representing a year-on-year decrease of approximately RMB152 million.- As at the end of 2025, Yuexiu REIT had RMB financing of approximately RMB15.47 billion, accounting for 76% of total financing (2024: RMB financing of approximately RMB12.33 billion, accounting for 60% of total financing).Mr. JIANG Guoxiong, Chairman and Non-Executive Director of Yuexiu REIT, said, "2025 marked the 20th anniversary of Yuexiu REIT's listing. The Manager consolidated its competitive advantages by taking strategic actions to secure market share, prioritised occupancy rates, strengthened risk control to stabilise lease renewals, enhanced product competitiveness to meet market demand and invested in capital renovation projects to ensure asset value preservation and appreciation. These efforts stabilised the fundamentals of operations in a challenging market, providing solid support for the full-year revenue. Concurrently, we optimised the asset portfolio by appropriately reducing the proportion of office buildings, and proactively captured favourable financing opportunities, successfully issuing the first-ever Panda Bonds by a listed REIT globally as well as the REIT’s inaugural green bond. Financing costs for the year reached a three-year low, effectively underpinning the overall distribution level. The successful execution of a series of pioneering capital operations fully demonstrated the Manager’s strategic commitment to driving the high-quality development of Yuexiu REIT. This underscored its resolute determination in creating sustainable and long-term value for Unitholders.”Guangzhou International Finance Center (GZIFC)During the year, GZIFC recorded a newly contracted area of 15,702 sq.m. The newly launched 7,403 sq.m. of furnished units recorded an absorption cycle of about 36 days, with an absorption rate close to 72%. Quality tenants introduced include two Fortune Global 500 companies, a Fortune China 500 company, a leading global shipping giant, and a renowned Internet-based culture, sports and entertainment company. In addition, the project recorded a renewal area of 34,294 sq.m. and a renewal rate of 86%, retaining quality tenants including six Fortune Global 500 companies and a foreign consulate. GZIFC was selected as one of the Top 30 companies in the “Performance Index - 2025 Commercial Property Operation Performance)” by Guandian.GZIFC Shopping Mall renewed lease with its anchor tenant, Guangzhou Friendship Store, and introduced China Duty Free Group (CDFG) to set up a store, which is the first and currently the only downtown duty-free store in Guangzhou. In addition, GZIFC Shopping Mall launched the light meal and beverage area on the basement floor, coupled with the brand revitalisation of the dining tenants on the fourth and fifth floors by introducing seven “first stores”. Membership operations achieved remarkable results, with the share of member sales doubling to 16%. The project actively created digitalised consumption scenarios and made full use of mainstream platforms to attract customer flow through multiple channels. Specifically, the “Italian Culture Season” themed event was successfully held in collaboration with hotels, theaters, museums and consulates, effectively boosting customer flow and sales. Newly contracted area and renewal area totaled 35,573 sq.m., with a renewal rate of 89%. The occupancy rate was 95.5%.Four Seasons Hotel Guangzhou launched the first batch of renovated rooms during the year. The average room rate was RMB2,260, representing a year-on-year increase of 5.8%. The average occupancy rate was 77.7%. The revenue per available room (RevPAR) was RMB1,756, representing a year-on-year increase of 0.9%. The RevPAR competitive index was 110.0, maintaining a relatively leading market position among luxury hotel competitors. Ascott Serviced Apartments GZIFC recorded an average occupancy rate of 91.5% during the year, representing a year-on-year increase of 1 percentage point. The average room rate was RMB1,137, representing a year-on-year increase of 1.6%. The RevPAR was RMB1,040, representing a year-on-year growth of 2.7%. The RevPAR competitive index reached 146.9, remaining at a high level among high-end apartment competitors. The Apartments achieved a record high in operating revenue for the same period and ranked first in operating revenue among Ascott China properties for ten consecutive years since 2016.Yuexiu Financial TowerThe Manager disposed of 50% interest in Yuexiu Financial Tower in Q4 2025. Following completion of the disposal, Yuexiu Financial Tower became a Qualified Minority-owned Property of the REIT. The occupancy rate was 77.9% at the end of the period.White Horse BuildingWhite Horse Building introduced high-quality customers from core industrial clusters in Guangzhou, Shenzhen and Dongguan and recorded a newly contracted area of 5,808 sq.m. for the year, with full occupancy on the 1st floor for the first time in the past five years and a six-year record high set by the 2nd floor’s occupancy rate. During the year, it organised 22 original brands to showcase their products at professional exhibitions such as the Fashion World Tokyo, and the China International Fashion Fair; held the “White Horse Fashion Journey: Border Trade Supply Chain Matching Conference”, and established the “Guangdong-Xinjiang Fashion Industry Chain Supply and Procurement Cooperation Alliance” with ten wholesale markets in Urumqi, Xinjiang. During the year, it welcomed a total of 517 procurement delegations, along with nearly 13,000 purchaser visits, including 19 foreign delegations from France, Vietnam and other countries, and facilitated procurement deals worth RMB320 million. The occupancy rate was 96.0% at the end of the period.Fortune PlazaDuring the year, the project recorded a newly contracted area of 6,334 sq.m., and introduced certain quality tenants including several subsidiaries of a Fortune Global 500 integrated financial group, two Fortune Global 500 companies and the Guangzhou branch of two global leading companies. The project recorded a renewal area of 8,662 sq.m. and a renewal rate of 84.0%, retained quality tenants including three Fortune Global 500 companies and the Guangzhou branch of a national commercial bank. Upgraded product standards accelerated the absorption of vacant units, with an absorption rate of 93% for furnished units. The occupancy rate was 93.4% at the end of the period, representing a year-on-year increase of 1 percentage point, and a strong rebound of 5.4 percentage points from the interim period.City Development PlazaDuring the Reporting Year, the project recorded a newly contracted area of 9,279 sq.m. and introduced a beauty technology company and a pharmaceutical supply chain service company to enhance the ambience of healthcare business in the building. The project recorded a renewal area of 5,011 sq.m. and a renewal rate of 77%, retained tenants including a Fortune Global 500 company and a globally-renowned Contract Research Organisation (CRO). The occupancy rate was 90.6% at the end of the period.Victory PlazaVictory Plazq’s anchor tenant, Uniqlo, continued to play a flagship role, recording a 7.0% year-on-year sales growth for the year and maintaining its position as the top-selling store nationwide. The project successfully introduced the sports brand “Super Anta” to set up the largest store in the Guangzhou-Foshan region and “Crab Mang Mang”, the first store nationwide of Guizhou spicy crab business, achieved the diversification of its food and beverage brand portfolio. By connecting internal and external resources to hold fifteen major events, the mall achieved a year-on-year increase of 2.0% in its annual sales. During the year, newly contracted area and renewal area totaled 5,579 sq.m., with a renewal rate of 84%. The occupancy rate was 94.0% at the end of the period.Shanghai Yue Xiu TowerDuring the year, Shanghai Yue Xiu Tower recorded a renewal area of 6,430 sq.m., with a renewal rate of 43%, while securing a newly contracted area of 8,070 sq.m., efficiently making up for the prematurely vacated units. During the year, the project continued to increase the supply of small-area furnished units to meet market demand, formulated differentiated pricing strategies, and successfully held a channel recruitment conference, which attracted more than one hundred real estate agencies. By investing in various capital nature renovations, the project enhanced both energy efficiency and service standards. The occupancy rate was 83.1% at the end of the period.Wuhan PropertiesDuring the year, Wuhan Yuexiu Fortune Centre recorded a newly contracted area of 26,837 sq.m., and introduced quality tenants including two Fortune Global 500 state-owned enterprises, and two Fortune Global 500 foreign enterprises. In addition, it recorded a renewal area of 20,617 sq.m. and a renewal rate of 76.0%, hitting a new high in the past three years, and retained quality tenants, including seven Fortune Global 500 enterprises and a Fortune China 500 company. Approximately 21,000 sq. m. of renovated units were supplied throughout the year, with an absorption rate approaching 98%. The occupancy rate was 62.1% at the end of the period, representing a year-on-year increase of 1 percentage point.Wuhan Starry Victoria Shopping Centre revitalised several popular dining and fitness brands, aiming to attract more family and young customer groups. The project deeply tapped into the consumption potentials of “night economy” and “scene experience” by leveraging the unique venue feature of “Joy Garden”, launching themed activities such as “Riverside Starry Night ”, thus achieving customer flow substantially in line with last year, while the shopping mall recorded a year-on-year increase of 0.5% in annual sales. During the year, newly contracted area and renewal area totaled 9,827 sq.m., with a renewal rate of 48.0%. The occupancy rate was 87.4% at the end of the period, representing a rebound of 5.0 percentage points from the interim period.Hangzhou VictoryDuring the year, the project recorded a newly contracted area of 7,890 sq.m. and introduced a tenant to take up an entire floor. In addition, it recorded a renewal area of 8,836 sq.m. and a renewal rate of 54%, retained quality tenants including two Fortune Global 500 companies and the Zhejiang branch of a state-owned enterprise in Shanxi Province. The occupancy rate was 84.5% at the end of the period.Integrating ESG into Business and Promoting Sustainable DevelopmentAdhering to a long-term perspective, the Manager systematically advanced ESG initiatives. On the occasion of publicly disclosing Yuexiu REIT’s sustainability practices for the tenth consecutive year, the Manager officially renamed the “Environmental, Social and Governance Report” to the “Sustainability Report”, further promoting the deep integration of Yuexiu REIT’s strategy into sustainable development and reinforcing their synchronized progress. During the year, Yuexiu REIT received the highest Green Five Star rating and the title of “Global Sector Leader” for the first time from the Global Real Estate Sustainability Benchmark (GRESB) and once again secured A-rating (highest level) for public disclosure, highlighting its outstanding capabilities in the field of sustainable development.ProspectsIn the coming year, the Manager will maintain a prudent and optimistic attitude, adapt proactively to changes and strengthen risk managemen to generate stable return for the Unitholders. In terms of asset management, the Manager will dynamically implement proactive, prudent and flexible leasing and operating strategies in response to economic development trends and competitive dynamics, diligently explore new growth drivers, and keenly seize potential opportunities to enhance the market competitiveness of asset portfolio. In terms of financing management, the Manager will continue to review and make reasonable adjustments to its financing structure, and introduce low-cost RMB financing through various financing channels to offset interest rate risks. In respect of renovation projects, the Manager will carry out the phased renovations of Four Seasons Hotel Guangzhou in an orderly manner to support the long-term preservation and appreciation of property value.About Yuexiu Real Estate Investment TrustYuexiu Real Estate Investment Trust ("Yuexiu REIT") was listed on the Hong Kong Stock Exchange of Hong Kong Limited on 21 December 2005 and is the first listed real estate investment trust only investing in properties in the People's Republic of China (the "PRC") in the world. As of 31 December 2025, Yuexiu REIT’s portfolio of properties consisted of ten properties (including one Qualified Minority-owned Property), namely, White Horse Building, Fortune Plaza, City Development Plaza, Victory Plaza, Guangzhou International Finance Centre (“GZIFC”), Yuexiu Financial Tower (a Qualified Minority-owned Property with a 49.495% beneficial interest) located in Guangzhou; Yue Xiu Tower located in Shanghai; Wuhan Yuexiu Fortune Centre, and Starry Victoria Shopping Centre located in Wuhan; Victory Business Centre located in Hangzhou; and Yue Xiu Building located in Hong Kong. The total gross floor area of the properties (excluding Yuexiu Financial Tower) was approximately 974,000 sq.m. All properties are located in the central business district of Guangzhou, Shanghai, Wuhan, Hangzhou and Hong Kong respectively. The categories of the properties include Grade-A offices, commercial complexes, retail business, hotel, serviced apartments and professional clothing market etc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
云顶新耀维适平(R)中国大陆首张处方落地 填补中重度溃疡性结肠炎治疗空白 ACN Newswire

云顶新耀维适平(R)中国大陆首张处方落地 填补中重度溃疡性结肠炎治疗空白

香港, 2026年3月11日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀(01952.HK)宣布,旗下自身免疫性疾病领域核心产品维适平(R)(精氨酸艾曲莫德片,VELSIPITY(R))中国大陆首张处方在3月9日于中山大学附属第一医院开出,标志着这款创新疗法正式进入中国临床应用阶段。据悉,在中国大陆首方开具当天,维适平(R)已在广州、上海、杭州、西安、重庆、北京和南京7个核心城市的8家三甲医院同步开出处方,实现上市首日即覆盖全国重点区域患者,并通过互联网医院渠道进一步扩大患者覆盖范围。目前,该药物已在中山大学附属第一医院、浙江大学医学院附属邵逸夫医院、中国人民解放军空军军医大学第一附属医院、重庆市人民医院、中国医学科学院北京协和医院等多家核心医疗机构惠及患者。值得关注的是,维适平(R)于今年2月获得国家药监局批准上市,仅一个月便实现中国大陆首方落地,推进速度明显快于行业平均水平。业内认为,这不仅反映出该产品较高的临床需求,也体现了云顶新耀在创新药商业化方面的执行效率。从疾病负担来看,炎症性肠病(IBD)已被认为是全球增长最快的消化系统疾病之一。IBD主要包括溃疡性结肠炎(UC)和克罗恩病(CD)。近年来,随着饮食结构变化、生活方式改变以及诊断水平提升,中国患者数量持续增加。多家行业研究机构预计,到2030年前后,中国IBD治疗市场规模有望突破百亿元人民币,其中新型小分子创新药将成为主要增长动力之一。从临床需求来看,溃疡性结肠炎是一种病因尚不明确、易复发的慢性肠道炎症性疾病,临床表现为黏液血便、腹痛、腹泻、里急后重等症状,严重影响患者长期生活质量。近年来,中国该病发病率和患病率持续上升且呈年轻化趋势,预计患者人数将由2025年的约98万增长至2031年的约150万。目前该病仍无法治愈,患者需长期用药维持疾病控制,而传统疗法疗效有限、生物制剂存在“疗效天花板”,临床亟需能实现更稳定、持久疾病控制的创新方案。维适平(R)作为每日口服一次的新一代高选择性S1P受体调节剂,具备最佳药物(best-in-disease)潜质,已获得美国胃肠病学协会(AGA)临床实践指南与美国胃肠病学会(ACG)临床指南强烈推荐,作为中重度溃疡性结肠炎的一线用药。多项全球临床研究证实其疗效与安全性良好,尤其在快速起效、实现无激素缓解及深度黏膜愈合方面具有明显临床优势。在迄今最大规模的中重度UC患者亚洲多中心III期临床研究(ENLIGHT UC)中,维适平(R)维持治疗40周,临床缓解率达48.1%,深度黏膜愈合率达51.9%,内镜正常化率达45.5%。数据显示,维适平(R)可实现强效深度黏膜愈合,从而改善疾病长期预后,并有助于降低复发及癌变风险。全球Ⅲ期ELEVATE研究的一项开放标签扩展研究数据证实,持续维适平(R)治疗3年,在观察病例中,86.8%患者实现临床应答,临床缓解率和黏膜愈合率均维持在约60%水平。全球临床研究随访5年的数据进一步表明其稳定且良好的安全性特征,整体耐受性良好。中华医学会消化病学分会前任主任委员、中山大学附属第一医院消化内科学术带头人陈旻湖教授指出,维适平(R)此次首张处方的开具,有望进一步优化溃疡性结肠炎的临床管理路径,推动疾病治疗向更高水平发展,实现黏膜愈合的治疗目标,惠及更多患者。云顶新耀首席执行官罗永庆表示,黏膜愈合是当前溃疡性结肠炎的治疗目标,尽早实现可大幅降低患者疾病复发率、住院率、手术率和癌变风险。维适平(R)可从源头控制肠道炎症,促进黏膜愈合,填补了中重度溃疡性结肠炎治疗领域的空白。作为一款治疗溃疡性结肠炎的创新一线治疗药物,维适平(R)兼具“疗效、安全性及方便性”三重优势,为患者提供长期疾病控制与生活质量改善的保障。此外,该药物于2024年和2025年被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录,在大湾区率先实现临床应用,且在真实诊疗场景中的表现与临床研究疗效、安全性一致。商业化层面,云顶新耀已通过肾科核心产品耐赋康(R)验证了成熟可复制的商业化能力。作为全球首个且目前唯一在中、美、欧获得完全批准的IgA肾病对因治疗药物,耐赋康(R)在2025年前三季度销售额突破10亿元,创造了非肿瘤产品的历史,成为过去十年慢病药进医保销售最好的产品。该产品的成功,验证了以“科学及商业洞察驱动的准入、医学、市场、销售一体化协同(A2MS)”为核心的创新药商业化运营平台,也为后续产品的市场拓展提供了可复用的体系与经验。此次维适平(R)首方快速落地,进一步印证了该平台的高效性,依托耐赋康(R)的渠道网络与市场准入经验,其有望复刻增长路径。从市场格局来看,长期以来中国溃疡性结肠炎治疗市场以传统免疫抑制剂和注射型生物制剂为主,这些方案存在口服便利性不足、长期安全性风险等问题。维适平(R)凭借差异化优势,被业界认为有望填补这一需求缺口,行业普遍预期其销售峰值可达50亿元,成为驱动云顶新耀业绩增长的重要引擎。云顶新耀表示,将构建多渠道准入体系,提供多元化患者援助项目和创新支付方案,并全力推动维适平(R)纳入国家医保目录,以提升药物的可及性和可负担性。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis JCN Newswire

Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis

HONG KONG, March 11, 2026 - (ACN Newswire via SeaPRwire.com) – March 9, Everest Medicines (1952.HK) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access in the region. According to reports, on the day the first prescription was issued in mainland China, VELSIPITY(R) was simultaneously prescribed in eight tertiary hospitals across seven key cities—Guangzhou, Shanghai, Hangzhou, Xi’an, Chongqing, Beijing, and Nanjing—achieving immediate coverage of patients in major regions nationwide on its launch day. The drug has also expanded patient access through internet hospital platforms. To date, patients at leading medical institutions, including the First Affiliated Hospital of Sun Yat-sen University, Sir Run Run Shaw Hospital, the First Affiliated Hospital of the Air Force Medical University of the People's Liberation Army, Chongqing People’s Hospital, and Peking Union Medical College Hospital, have already benefited from the therapy.Notably, VELSIPITY(R) was approved for marketing by China’s National Medical Products Administration (NMPA) in February this year. The first prescription in mainland China was issued just one month later, marking a rollout significantly faster than the industry average. Industry observers believe this not only reflects the strong clinical demand for the product but also demonstrates Everest Medicines’ execution capabilities in the commercialization of innovative drugs.From a disease burden perspective, inflammatory bowel disease (IBD) is considered one of the fastest-growing gastrointestinal diseases worldwide. IBD mainly includes ulcerative colitis (UC) and Crohn’s disease (CD). In recent years, the number of patients in China has continued to increase, driven by changes in dietary patterns, shifts in lifestyle, and improvements in diagnostic capabilities. Several industry research institutions predict that China’s IBD treatment market could exceed RMB 10 billion by around 2030, with novel small-molecule innovative drugs expected to become one of the key drivers of market growth.From a clinical perspective, ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease characterized by symptoms such as mucus and blood in the stool, abdominal pain, diarrhea, and rectal tenesmus, which can significantly affect patients’ quality of life. In China, both the incidence and prevalence of UC are increasing, with a clear trend toward younger patients. The patient population is projected to grow from approximately 0.98 million in 2025 to about 1.50 million by 2031. As the disease remains incurable, patients require long-term management to maintain disease control.VELSIPITY(R) is a next-generation, highly selective S1P receptor modulator with best-in-disease potential and strong first-line treatment recommendations for moderately to severely active ulcerative colitis (UC) in both the American Gastroenterological Association (AGA) Clinical Practice Guideline and the American College of Gastroenterology (ACG) Clinical Guideline Update.Results from multiple global clinical studies have demonstrated that VELSIPITY(R) delivers meaningful clinical benefits, including rapid onset of action, long-lasting clinical remission, steroid-free remission, and deep mucosal healing, with a favorable safety profile. In the ENLIGHT UC study, the largest Asian multicenter Phase 3 clinical study, the clinical remission rate at week 40 of the maintenance period reached 48.1%, and the deep mucosal healing rate reached 51.9%, with an endoscopic mucosal normalization rate of 45.5%. These findings demonstrate VELSIPITY(R)'s potential to improve long-term disease outcomes and reduce the risk of relapse and disease progression.Results from the ELEVATE UC open-label extension demonstrate continuous treatment with VELSIPITY(R) for up to 3 years resulted in 86.8% of patients achieving a clinical response among the observed cases, with both clinical remission and mucosal healing rates maintained at approximately 60%. Safety data extending up to five years from the global clinical program further confirm that VELSIPITY(R) is well tolerated and maintains a favorable and stable safety profile.Prof. Chen Minhu, Academic Leader of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University, noted that with the first prescription now issued, VELSIPITY(R) is being incorporated into routine clinical practice, providing physicians with an innovative treatment option for patients living with UC who continue to face ongoing disease challenges.“Early achievement of mucosal healing is recognized as a key treatment goal, as it can significantly reduce rates of disease relapse, hospitalization, surgery, and the risk of progression to colorectal cancer. VELSIPITY(R) addresses this need by targeting intestinal inflammation at its source and promoting mucosal healing, while offering a favorable profile of efficacy and safety, along with the convenience of an oral, once-daily regimen, supporting sustained disease management and improving patients' quality of life,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.In 2024 and 2025, VELSIPITY(R) was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. Real-world data have shown that the efficacy and safety of VELSIPITY(R) are consistent with those observed in clinical trials.From a commercialization perspective, Everest Medicines has already demonstrated a mature and replicable capabilities through its core nephrology product NEFECON(R). As the world’s first and currently the only etiological treatment for IgA nephropathy (IgAN) to receive full approvals in China, the United States, and Europe, Nefecon(R) generated more than RMB 1 billion in sales in the first three quarters of 2025. The product has set a new benchmark for non-oncology therapies and has become one of the best-performing chronic disease drugs added to China’s national reimbursement list over the past decade.This achievement has validated the company’s platform for the commercialization of innovative medicines, centered on the integrated coordination of access, medical, marketing, and sales (A2MS) driven by scientific and commercial insights. It has also provided replicable systems and experience for the market expansion of future products. The rapid issuance of the first prescription for VELSIPITY(R) further demonstrates the efficiency of this platform. Leveraging the channel network and market access experience built through Nefecon(R), the product is expected to replicate a similar growth trajectory.From a market landscape perspective, China’s UC treatment market has long been dominated by traditional immunosuppressants and injectable biologics. However, these therapies present certain limitations, including lack of oral convenience and potential long-term safety risks. With its differentiated advantages, VELSIPITY(R) is widely viewed by the industry as having the potential to address this unmet need. Market expectations suggest that the drug could reach peak sales of RMB 5 billion, becoming a key driver of revenue growth for Everest Medicines.Everest Medicines stated that it plans to build a multi-channel market access framework, provide diversified patient assistance programs and innovative payment solutions, and actively pursue the inclusion of VELSIPITY(R) in China’s National Reimbursement Drug List (NRDL) to improve the drug’s accessibility and affordability. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
越秀房产基金经营保持韧性 2025年收入逾人民币18亿元 ACN Newswire

越秀房产基金经营保持韧性 2025年收入逾人民币18亿元

香港, 2026年3月11日 - (亚太商讯 via SeaPRwire.com) - 越秀房地产投资信托基金( 〝越秀房产基金〞,连同越秀房托资产管理有限公司,统称〝基金〞;股份代号:405)公布其截至2025年12月31日止之全年业绩。越秀房产基金管理团队:主席及非执行董事江国雄先生(中)、执行董事及行政总裁区海晶女士(左)、财务总监关志辉先生(右)2025年全年业绩摘要:- 整体经营保持韧性,收入总额为人民币18.56亿元(2024年:人民币20.32亿元)。- 平均融资成本为3.61%,创近三年新低;平均付息率3.77%,同比下降76个基点,剔除汇兑亏损的融资成本同比减少约1.52亿元人民币。- 于2025年12月31日,物业整体出租率为82.1%(2024年同期:84.5%)。- 优化资产组合,于第四季度出售越秀金融大厦50%权益,回笼约人民币53亿元现金提升财务灵活度,获标普和惠誉维持〝投资级〞评级,并上调评级展望至〝稳定〞。- 末期分派每个基金单位约人民币0.0189元,约等于0.0214港元。全年度之每个基金单位分派约人民币0.0522元,约等于0.0580港元。按年计算的分派收益率为6.74%。- 为保持基金财务灵活性,于2025年7月1日至2025年12月31日期间的分派比率调整为90%,全年整体分派比率约为96%。广州国金中心:- 广州国金中心综合体录得经营收入为人民币9.84亿元,占基金收入总额53.0%。- 广州国金中心写字楼引进两家财富世界500强企业;出租率为80.9%。- 国金天地引进广州首家且目前唯一的市内免税店〝中免免税店〞,全年续租率89%,期末出租率95.5%。- 广州四季酒店平均房价同比提升5.8%,国金中心雅诗阁服务式公寓平均入住率达91.5%,同比增长1个百分点,营业收入创历史同期新高。积极管理融资风险,有效平抑融资成本- 针对2025年到期的人民币5.3亿元短期贷款、21亿港元5年期银团贷款以及38亿港元3年期银团贷款余下21亿港元,管理人于2025年完成人民币5.3亿元短期贷款续借,并通过取得17亿元人民币离岸贷款、发行10亿人民币点心债以及21亿港元等值境外银团组合贷款(为可持续发展挂钩贷款),用于到期贷款的再融资,确保流动性风险得到有效管控。- 年内合计引入人民币46.8亿元贷款,并部分置换境外浮息港元贷款,利用人民币融资相对低位,主动调节融资结构。2025年年末融资利率敞口约为10%,较年初26%收窄16个百分点;平均融资成本为3.61%,创近三年新低,较年初4.16%下降55个基点;2025年全年平均付息率3.77%,同比下降76个基点。剔除汇兑亏损的融资成本约为人民币7.73亿元,同比减少约人民币1.52亿元。- 2025年年末人民币融资约154.7 亿元,占总体融资76%(2024年:人民币融资约123.3 亿元,占总体融资60%)。越秀房产基金主席及非执行董事江国雄先生表示:〝2025年是越秀房产基金上市二十周年。管理人巩固优势,策略性抢占市场份额,以出租率为优先考虑,强化风险管控稳定续租,匹配市场需求增强产品竞争力,投入资本性改造确保资产保值增值,在充满挑战的市场中稳定经营基本面,为全年经营收入提供坚实支撑。与此同时,我们优化资产组合,适当降低写字楼业态占比,并敏锐捕捉有利融资窗口,先后成功发行全球首笔上市REITs‘熊猫债’及基金首笔绿债。全年融资成本创近三年新低,有效支撑整体分派水平。一系列开创性资本运作的成功实施,充分彰显管理人推动越秀房产基金高质量发展的战略目标,展现管理人为基金单位持有人创造可持续长远价值的坚定决心。〞国金中心国金中心年内新签15,702平方米。推出7,403平方米带装修单元,去化周期约36天,去化率接近72%。引进优质租户包括两家财富世界500强背景企业、一家财富中国500强企业、一家全球龙头航运企业和一家知名互联网背景文体娱乐企业,续租34,294平方米,续租率86%,留存优质租户包括六家财富世界500强企业和一家外国领事馆。国金中心入选观点〝表现力指数·2025商办资产运营表现〞TOP30榜单。国金天地完成主力租户〝广州友谊商店〞续租;引进广州首家且目前唯一的市内免税店〝中免免税店〞;落地负一层轻餐茶饮区、四楼和五楼餐饮业态品牌焕新,引进七家〝首店〞。会员运营成效显著,会员销售占比翻倍式提升至16%。积极打造电子化消费场景,充分利用主流平台多渠道引流。联动酒店、大剧院、博物馆、领事馆成功举办〝意大利文化季〞主题活动,有效促进客流与销售转化。新签和续租合计35,573平方米,续租率89%。出租率为95.5%。广州四季酒店年内首批改造客房年内入市,平均房价为人民币2,260元,同比提升5.8%,平均入住率为77.7%;每间可供出租客房收入(RevPAR)为人民币1,756元,同比增长0.9%;RevPAR竞争指数为110.0,在奢华酒店竞争群组中始终保持较领先的市场地位。国金中心雅诗阁服务式公寓期内平均入住率为91.5%,同比上升1个百分点;平均房价为人民币1,137元,同比提升1.6%;RevPAR为人民币1,040元,同比增长2.7%;RevPAR竞争指数达146.9,在高端公寓竞品市场中维持高位。公寓营业收入创历史同期新高,经营收入自2016年起连续十年稳居雅诗阁集团中国区第一名。越秀金融大厦管理人于第四季度出售越秀金融大厦50%权益。出售完成后,越秀金融大厦成为基金合资格少数权益物业。期末出租率为77.9%。白马大厦白马大厦引入广州、深圳和东莞核心产业集群优质客户,带动全年新签5,808平方米,一楼实现近五年首次满租,二楼出租率创近六年新高。年内组织22家原创品牌亮相日本东京时尚产业展、及中国国际服装服饰博览会等专业展会;开展〝白马时尚行 · 边贸供应链对接会〞,与新疆乌鲁木齐十家批发市场建立〝粤新服饰产业链供采合作联盟〞。全年累计接待517个采购团,累计接待采购商近1.3万人次,其中包括来自法国、越南等19个外商团,促成采购金额达人民币3.2亿元。期末出租率为96.0%。财富广场财富广场全年新签6,334平方米,成功引进多家优质租户,包括一家财富世界500强综合金融集团旗下多家企业、两家财富世界500强背景企业和两家全球行业龙头企业的广州分支机构。续租8,662平方米,续租率84.0%,包括三家财富世界500强背景企业和一家全国性商业银行广州分行。升级产品标准加快空置单元去化,带装修单元去化率达93%。期末出租率为93.4%,同比上升1个百分点,出租率较中期强劲回升5.4个百分点。城建大厦城建大厦年内新签9,279平方米,引进一家美容科技企业和一家医药供应链服务企业,提升楼内大健康业态氛围。续租5,011平方米,续租率77%,包括一家财富世界500强企业和一家全球知名合同研究组织(CRO)企业。期末出租率为90.6%。维多利广场维多利广场主力租户〝优衣库〞继续发挥旗舰作用,全年销售额同比增长7.0%,蝉联全国门店榜首。成功引进运动品牌〝超级安踏〞,打造广佛地区最大门店;成功引入贵州香辣蟹全国首店〝蟹莽莽〞,丰富餐饮品牌组合。联动内外部资源举办十五场大型活动,实现商场全年销售额同比增长2.0%。全年新签和续租合计5,579平方米,续租率84%。期末出租率为94.0%。上海越秀大厦上海越秀大厦全年续租6,430平方米,续租率43%;新签8,070平方米,有效填补退租单元。持续匹配市场需求增加小面积带装修单元供应,制定差异化定价策略,成功举办渠道招商会,吸引百家中介机构参与,并投入多项资本性改造推动节能效益和服务水平持续提升。期末出租率为83.1%。武汉物业武汉越秀财富中心年内新签26,837平方米,引进优质租户包括两家财富世界500强背景央企和两家财富世界500强背景外资企业。续租20,617平方米,续租率76.0%创近三年新高,留存优质租户包括七家财富世界500强背景企业和一家财富中国500强背景企业。全年改造单元供应约2.1万平方米,去化率接近98%。期末出租率为62.1%,同比上升1个百分点。武汉星汇维港购物中心年内焕新多家热门餐饮和健身品牌,吸引更多家庭和年轻客群,依托〝悦花园〞场地特色深度挖掘〝夜经济〞与〝场景体验〞消费潜力,举办〝江畔星夜〞主题活动,实现客流量同比基本持平,商场年度销售额同比提升0.5%。全年新签和续租合计9,827平方米,续租率48.0%。期末出租率为87.4%,较中期回升5.0个百分点。杭州维多利杭州维多利全年新签7,890平方米,引进一家全层租户。续租8,836平方米,续租率54%,留存优质租户包括两家财富世界500强背景企业和一家山西省属国企的浙江分公司。期末出租率为84.5%。ESG融合业务,推进可持续发展管理人秉承长期主义理念,系统布局ESG工作,值此连续第十年对外披露越秀房产基金可持续发展实践之际,管理人正式将〝环境、社会及管治报告〞更名为〝可持续发展报告〞,以此进一步促进越秀房产基金战略与可持续发展深度融合、同频共进。年内,首次荣获全球房地产可持续发展基准(GRESB)最高绿色五星评级及〝全球行业领导者〞称号,公开披露再次获最高〝A〞级等,彰显了在可持续发展领域的卓越实力。未来展望未来一年,管理人将保持审慎乐观的态度,〝以变应变〞强化风险管理,致力为基金单位持有人创造稳定回报。资产管理方面,将因应经济发展走势和竞争环境演变,动态实施积极、稳健、灵活的租赁和营运策略,发掘新增长点、把握潜在机会提升资产组合市场竞争力。融资管理方面,将持续对融资结构进行合理调整,通过各类融资途径引入低成本人民币融资,平滑利率风险。工程改造方面,将有序分段改造广州四季酒店,护航物业长效保值增值。关于越秀房地产投资信托基金越秀房地产投资信托基金(〝越秀房产基金〞)于2005年12月21日在香港联交所上市,为全球首只投资于中国内地物业的上市房地产投资信托基金。截至2025年12月31日,越秀房产基金之物业组合共有十项(包括一项合资格少数权益物业),分别位于广州的白马大厦、财富广场、城建大厦、维多利广场、广州国际金融中心、越秀金融大厦(合资格少数权益物业,实益权益49.495%)、位于上海的越秀大厦、位于武汉的武汉越秀财富中心、星汇维港购物中心、位于杭州的维多利商务中心及位于香港的越秀大厦。不包括越秀金融大厦,物业总建筑面积约为97.4万平方米,分别位于中国广州市、上海市、武汉市、杭州市及香港市的核心商业区域。物业类型包括甲级写字楼、商业综合体、零售商业、酒店、服务式公寓、服装专业市场等。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

Dangbei 春季促销:热门家庭影院投影仪最高可享 33.9% 折扣

(SeaPRwire) - 今年春天,利用Amazon UK上顶级Dangbei投影仪的大幅优惠,焕新你的家庭娱乐体验本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More

欧洲药品管理局授予TolerogenixX公司的MIC-Lx疗法用于肾移植中供体特异性免疫耐受的PRIME认定

MIC-Lx疗法因其有潜力减少或消除终身免疫抑制疗法而获得欧洲药品管理局的PRIME认定长达10年随访的长期临床数据支持其持续安全性和免疫抑制的减少 (SeaPRwire) - 德国海德堡,2026年3月11日讯 — TolerogenixX是一家临床阶段的生物制药公司,致力于开发个性化细胞疗法,以在器官移植和自身免疫性疾病中诱导持续的免疫耐受。该公司今日宣布,欧洲药品管理局(EMA)已授予其主要细胞疗法候选产品MIC-Lx PRIority MEdicines(PRIME)认定,用于活体供肾移植中的个体化免疫抑制。PRIME计划支持针对有重大未满足医疗需求的严重疾病的药物,并与EMA提供早期和加强的监管互动,以加速临床开发和患者获取。 肾移植是终末期肾病的首选治疗方法,但患者需要终身进行全身免疫抑制治疗以防止器官排斥。这些治疗会带来显著的副作用,包括感染、恶性肿瘤和代谢并发症。TolerogenixX的MIC-Lx疗法(用于活体供体移植的改良免疫细胞)旨在诱导供体特异性免疫耐受,有可能使移植受者大幅减少慢性免疫抑制。 该PRIME认定是在高级治疗委员会(CAT)进行积极评估并在2026年2月的会议上获得人用药品委员会(CHMP)认可之后做出的。根据EMA的评估,现有的临床和非临床数据支持这样的假设,即用细胞抑制剂处理的改良供体免疫细胞可能会在移植受者中诱导出耐受性免疫状态。 针对肾移植患者的临床I期和正在进行的II期研究,随访数据长达10年,支持了所提出的作用机制,并表明: 无供体特异性抗体反应免疫抑制治疗大幅减少机会性感染减少。 I期研究的5年随访数据于2023年发表在《免疫学前沿》上,显示出持久的供体特异性免疫调节,同时调节性B淋巴细胞持续增加。 “EMA的PRIME认定是对我们的MIC技术改善当前移植治疗模式潜力的重要认可,”TolerogenixX首席执行官Matthias Schaier教授博士说。“我们的目标是实现供体特异性免疫耐受,减轻移植患者慢性免疫抑制的负担。迄今为止产生的临床数据表明,我们的MIC疗法可能为肾移植受者提供一种有效的治疗选择,同时减少通常与长期免疫抑制相关的副作用。” 该公司计划在2027年上半年公布正在进行的IIb期试验的数据。 ### 关于TolerogenixXTolerogenixX是一家私人持有的生物制药公司,致力于开发新型的个性化疗法,以在移植和自身免疫性疾病中诱导抗原特异性免疫耐受。其专有的MIC(改良免疫细胞)技术旨在以靶向方式调节免疫系统,有可能减少长期全身免疫抑制的需求。 该公司的主要候选产品MIC-Lx已在肾移植受者中完成了Ib期临床试验(TOL-1),显示单次给药后具有持续的安全性和耐受性,同时保留正常的免疫反应。IIb期研究(TOL-2)目前正在进行中。 TolerogenixX成立于2016年,总部位于德国海德堡。 关于MIC治疗MIC治疗是一种个性化细胞疗法,通过一种新颖的作用方式调节免疫系统,以实现特异性和持续的免疫耐受。它不仅可以使移植受者受益,还可以使自身免疫性疾病患者,如系统性红斑狼疮和多发性硬化症患者受益。 MIC生产快速、安全且有效。使用通过白细胞分离术获得细胞,MIC可以在24小时内制造出来。由于采用标准化程序,MIC生产可以轻松扩大规模,并通过TolerogenixX开发的专有方法在全球范围内提供。 联系方式TolerogenixX GmbHMatthias Schaier教授博士新海德堡菲尔德162号D-69120海德堡/德国schaier@tolerogenixX.com电话:+49 162 2638005 akampionLudger Weß博士/Ines-Regina Buth管理合伙人info@akampion.com电话:+49 40 88 16 59 64电话:+49 30 23 63 27 68本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More

36氪控股公司将于2026年3月17日(星期二)公布2025年下半年及财年财务业绩

(SeaPRwire) - 北京,2026年3月11日讯 -- 36氪控股公司(“36氪”或“公司”)(纳斯达克股票代码:KRKR)是中国一个知名品牌,也是一个开创性平台,致力于服务新经济参与者。该公司今日宣布,将于2026年3月17日(星期二)美国股市开盘前公布其2025年下半年及全年未经审计的财务业绩。 公司管理层将于美国东部时间2026年3月17日上午8点(北京时间/香港时间2026年3月17日晚上8点)举行收益电话会议。 希望通过电话参加会议的人士,请访问以下链接完成预注册,并在预定的会议开始时间前5分钟拨入。注册后,每位参与者将收到加入电话会议的拨入详细信息。 活动名称:36氪控股公司2025年下半年及全年收益电话会议预注册链接:https://s1.c-conf.com/diamondpass/10053735-6wo0i8.html 此外,电话会议的直播和存档网络广播将在公司投资者关系网站http://ir.36kr.com上提供。 会议结束后一周内,可通过拨打以下电话号码收听电话会议重播: 美国:+1-855-883-1031国际:+61-7-3107-6325中国香港:800-930-639中国内地:400-120-9216重播密码:10053735 关于36氪控股公司 36氪控股公司是一个知名品牌,也是一个开创性平台,致力于服务中国新经济参与者,其使命是助力新经济参与者取得更大成就。公司最初以提供高质量的新经济相关内容起步,通过多样化的分发渠道覆盖中国新经济的多个行业。借助高质量内容带来的流量,公司已将业务扩展到商业服务领域,包括在线广告服务、企业增值服务和订阅服务,以满足新经济公司不断变化的需求以及传统公司的升级需求。公司拥有全面的数据库和强大的数据分析能力。通过多样化的服务产品和显著的品牌影响力,公司有能力持续挖掘中国新经济的高增长潜力。 如需更多信息,请访问:http://ir.36kr.com。 投资者和媒体咨询,请联系: 在中国: 36氪控股公司投资者关系电话:+86 (10) 8965-0708电子邮件:ir@36kr.com Piacente Financial Communications蔡珍妮电话:+86 (10) 6508-0677电子邮件:36Kr@tpg-ir.com 在美国: Piacente Financial Communications布兰迪·皮亚琴特电话:+1-212-481-2050电子邮件:36Kr@tpg-ir.com 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
MarketingPulse and eTailingPulse open next Thursday ACN Newswire

MarketingPulse and eTailingPulse open next Thursday

HONG KONG, Mar 11, 2026 - (ACN Newswire via SeaPRwire.com) – Organised by the Hong Kong Trade Development Council (HKTDC), MarketingPulse and eTailingPulse – Asia’s premier annual e-commerce and marketing events – will be held concurrently on 19 March at the Hong Kong Convention and Exhibition Centre (HKCEC). Under the theme "Generate New Growth", this year's conferences focus on how brands can rethink their growth strategies amid global market uncertainty, helping to turn challenges into forward momentum. From strategic insights to practical implementation, the events will comprehensively reveal new directions for growth, bringing together about 70 global e-commerce experts, marketing executives, brand representatives and advertising elites to share valuable insights and success stories relating to global marketing and e-commerce trends. Featuring 30 thematic sessions, seminars and demonstration sessions, the events will help to foster cross-sector exchange and boost collaboration within the industry.The rise of e-commerce has injected new momentum into global economic growth, while the government is actively encouraging small and medium-size enterprises (SMEs) to develop e-commerce capabilities that can enhance their market competitiveness. This year’s conferences will focus on the latest developments in e-commerce, helping participants seize growth opportunities in the current market environment through a dual-track approach that advances both e-commerce development and brand marketing. A lineup of experts will speak on topics such as agentic AI, lifestyle e-commerce, quick commerce and global brand expansion. They will examine innovation in e-commerce along with global marketing trends and emerging consumer opportunities, while exploring how the industry can generate new growth amid a rapidly evolving marketing landscape.Tech marketing expert shares insights on data-driven growthJinhee Lee, Chief Operating Officer of Olive Young, South Korea’s leading health and beauty brand, will present on the theme “Beyond Retail, Building an Ecosystem: Driving Collaborative Growth of Olive Young and K-Beauty”. Drawing on perspectives from both marketing and e-commerce, he will explain how seamless omnichannel operations and data-driven marketing strategies are being leveraged to build a high-growth ecosystem for Korean beauty brands, while continuously expanding their global footprint. Well-known for harnessing data to drive innovation, Mr Lee has spearheaded a series of digital transformation initiatives and integrated retail strategies, using technology to enable Olive Young to stay ahead of trends and become a leader in the global beauty market.Breaking new ground in marketing through the China experience and new retailAtour Group is a leading player in Chinese Mainland’s mid- to high-end hotel chain market. Its Founder, CEO & Chief Experience Officer, Haijun Wang, will focus on two key themes during his presentation: 1) Experience Differentiation Strategy — placing differentiated experiences at the core to build distinctive product and service offerings across both the hotel and retail businesses; and 2) Customer Segment Operations Strategy — using a core customer base that pursues a quality lifestyle as the connective thread to deeply integrate the hotel and retail businesses, thereby shaping a unique brand group model.Enhancing brand value through aesthetic intelligence in e-commercePauline Brown, former Chairman of LVMH North America, will share how to leverage "aesthetic intelligence" to elevate brand value, shape consumer perception and strengthen overall online-to-offline experiences and marketing strategies. She will also discuss how brands can continuously cultivate "taste" and aesthetic acumen and explain how aesthetics and elevated storytelling can be utilised to build truly compelling brands in a rapidly changing e-commerce and technological landscape.Exploring the latest trends in agentic AI and quick commerceQuick commerce and agentic AI are bringing unprecedented changes to the e-commerce market in the Chinese Mainland, continuously reshaping consumers' shopping patterns, habits and demands. Yatong Qiu, Vice President of Taobao&Tmall Group, Alibaba, will share on how brands and merchants can tackle demand through flexible merchandising strategies, real-time marketing and speed-oriented innovations to maintain competitiveness and seize time-sensitive opportunities. Meanwhile, Terry Li, Vertical General Manager of Smart Retail, Tencent, will take a deeper dive into agentic AI-driven e-commerce strategies. Looking from the perspectives of service providers and e-commerce ecosystems, he will share practical approaches and future innovation directions for agentic AI solutions, helping brands and businesses seize the initiative in the new era of e-commerce.Decoding cross-border growth and market entry strategies for ASEANAs ASEAN continues to rise as one of the world's most dynamic economic regions, enterprises from the Chinese Mainland and Hong Kong are actively setting their sights on Southeast Asia, particularly seeking growth opportunities through e-commerce channels. The conferences will feature a session titled “Decoding the Gateway to ASEAN: Cross Border Growth and Market Entry Strategies”, exploring strategies for entering the ASEAN market. Speakers including Luca Barni, SVP, Commercial, Lazada Group, will share their practical experiences in expanding within ASEAN. Attendees will get a comprehensive understanding of the growth opportunities and common pitfalls in this growing market, addressing e-commerce legal and regulatory challenges, as well as brand and product localisation strategies.Cracking the Threads audience engagement plus celebrity insightsThe recent rise of social platform Threads is further driving the evolution of brand marketing models. In the "Threads for Consumer and Audience Engagement" session, Kenie Kwok, Creative Strategy Lead at Meta, will share the latest trends in brand account management and user preferences from the platform's perspective. Actor and "Threads Admin" Ng Siu-hin will share his insights on how to stand out as a content creator, offering practical tips on building engagement with netizens from a creator's viewpoint. In addition, IN.DECIDE, renowned for managing social media platforms for multiple brands as an "admin", will analyse its promotional campaign for the film Peg O' My Heart, detailing how the virtual character "Choi San-keung" successfully broke the fourth wall with the audience.This year's "Meet the Celebrity” dialogue series has invited actor and singer-songwriter Louis Cheung to speak on the topic "Chasing the Golden Boy Within". He will share his career journey in personal brand management and talk about his multifaceted development across the acting, music and creative fields. Meanwhile, content creator and MUSE TV Founder Mayao will discuss how he strategically leverages innovative promotional approaches to market music works, generating broad and lasting public impact and driving sustainable market growth.Exploring the “healing economy" and IP marketingWhen engaging with younger generations, who place strong emphasis on emotional connection, brands must understand “oshikatsu culture”, where young people identify strongly as a fan of an idol, along with the healing trend and intellectual property (IP)-driven consumer behaviour. The session "Healing Economy and IP Marketing" will feature speakers including Yiying Wang, Founder and Designer of Noodoll Limited, who will explore how brands can keep abreast of the latest trends, such as designing sustainably interactive experiences and campaigns with an "oshikatsu mindset", incorporating healing elements into products or marketing to enhance resonance, and collaborating with popular IPs to boost reach and engagement, thereby deepening connections and relationships with younger demographics.The conferences will introduce a new feature, "e-Commerce Connect", showcasing the latest one-stop e-commerce solutions, with close to 30 local and international exhibitors. Additionally, a series of digital marketing and e-commerce workshops will enable participating brands to gain hands-on practical experience. Multiple networking activities will be organised, and participants can take advantage of one-to-one business matching services to facilitate cross-sector exchange and collaboration. The event will also feature live music performances, including a set from popular local singer James Ng.For more information on speakers and the detailed programme for the conferences, please visit: https://marketingpulse.hktdc.com/conference/mp/en. To request interviews with guest speakers, please email betsytse@raconteur.hk or molisalau@raconteur.hk.Photo download: https://bit.ly/3OU0UArPauline Brown, Former Chairman of LVMH North AmericaHaijun Wang, Founder and CEO of Atour Lifestyle HoldingsJinHee Lee, Chief Operating Officer of Olive YoungLouis Cheung, Actor and singer-songwriterNg Siu-hin, Artist and "Threads Admin"MarketingPulse and eTailingPulse will be held on 19 March at the Hong Kong Convention and Exhibition Centre. Pictured are the MarketingPulse and eTailingPulse events held in 2025Websites· MarketingPulse: https://marketingpulse.hktdc.com/conference/mp/en· Event schedule: https://marketingpulse.hktdc.com/conference/mp/en/programme· Speaker list: https://marketingpulse.hktdc.com/conference/mp/en/speaker· eTailingPulse: https://etailingpulse.hktdc.com/conference/etp/en· EntertainmentPulse: https://hkfilmart.hktdc.com/conference/hkfilmart/en Media enquiriesFor enquiries, please contact:Raconteur PR Agency:Betsy TseTel: (852) 9742 7338Email: betsytse@raconteur.hkMolisa LauTel: (852) 6187 7786Email: molisalau@raconteur.hkHKTDC Communication and Public Affairs Department:Clayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

Bamboo Digital Technologies 以数字银行与电子钱包软件解决方案定义2026年金融科技格局

(SeaPRwire) - 香港,2026年3月11日 -- 软件开发公司Bamboo Digital Technologies (BambooDT)今日发布了其“Vision 2026”企业基础设施套件。随着金融机构加速采用人工智能驱动技术,BambooDT正将自身定位为亚洲及全球市场数字银行软件开发和支付软件开发领域的首要合作伙伴。 在2026年不断发展的金融生态系统中,传统银行业与现代数字金融之间的差距持续缩小。BambooDT升级后的技术栈通过为数字银行、传统银行和支付提供商提供高性能解决方案,来应对这一转变。 “要在2026年取得成功,金融机构需要的不仅仅是一个应用程序——他们需要可扩展的基础设施,”BambooDT的首席执行官表示。“无论是推出白标数字钱包还是完整的数字银行软件解决方案,我们的平台都能提供当今金融市场所需的速度、安全性和合规性。” 以三大关键支柱革新金融基础设施: 1. 新一代数字银行与核心系统BambooDT帮助机构从遗留系统迁移到云原生架构。其数字银行软件开发套件支持灵活部署,为快速市场进入提供云原生SaaS银行平台,并为嵌入式金融扩展提供银行即服务(BaaS)基础设施。对于初创企业,公司提供数字银行应用开发服务和小额信贷银行软件,能够快速部署集成了开放银行API功能的网上银行系统。 2. 先进的电子钱包与支付网关作为领先的电子钱包应用开发公司,BambooDT提供支持跨境支付基础设施的白标数字钱包解决方案。该平台包含能够处理实时支付(RTP)的定制支付网关开发。此外,支付交换软件解决方案与商户收单软件集成,为现代支付生态系统创建了简化的移动钱包应用架构。 3. 创新的卡发行与管理BambooDT的卡软件开发团队推出了升级的卡管理系统(CMS),以支持现代卡项目。该平台支持虚拟卡发行、预付卡管理和信用卡处理,同时还提供智能卡个性化和令牌化服务提供商(TSP)功能,以增强实体卡和数字卡的安全性。 关于Bamboo Digital TechnologiesBamboodt (Bamboo Digital Technologies Co., Limited) 是一家在香港注册的软件开发公司,专注于安全、可扩展且合规的金融科技解决方案。我们帮助银行、金融科技公司和企业构建可靠的数字支付系统,从定制电子钱包和数字银行平台到端到端的支付基础设施。 媒体联系:公司: Bamboo Digital Technologies Co., Limited邮箱: info@bamboodt.com网站: https://www.bamboodt.com/本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting JCN Newswire

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting

TOKYO, Mar 11, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai’s anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease (AD), at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026) from March 17-21, in Copenhagen, Denmark, and online. The lecanemab data and additional research findings from Eisai’s AD portfolio will be featured in six presentations, including three oral presentations. Eisai will host an industry-sponsored symposium.Oral and Poster PresentationsOral presentations will include the latest findings from a United States real-world long-term treatment persistence study, and efficacy and safety outcomes in apolipoprotein E ε4 (ApoEε4) homozygous carriers in a U.S. multicenter real-world study. In addition, four-year data from the Clarity AD Open-Label Extension trial in ApoEε4 non-carriers and heterozygotes, and a genome-wide association study on novel genetic variants associated with cognitive decline in AD will be presented as posters.Eisai Symposium – Continue Life Their Way: Early Intervention in Alzheimer’s DiseaseEisai is sponsoring a symposium featuring four leading global experts in the field of AD, on the topics of why early intervention matters, continuing early AD treatment and real-world outcomes. The symposium aims to enhance understanding of the value of early and continued anti-amyloid treatment in early AD by exploring how real-world evidence can support confident patient assessment in clinical practice, and how to recognize AD as a chronic condition that requires a multidisciplinary approach to care.Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.AD/PD 2026 Presentations Relating to Eisai's Key Compounds and ResearchFor more information, please visit: https://www.eisai.com/news/2026/pdf/enews202612pdf.pdfMedia Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120Eisai Europe, Ltd.(Europe, Australia, New Zealand and Russia)EMEA Communications Department+44 (0) 7739-600-678EMEA-comms@eisai.netEisai, Inc. (U.S.)Julie Edelman+1-862-213-5915Julie Edelman@eisai.comAbout Lecanemab (generic name, brand name: Leqembi)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 7 countries including the U.S., China, the UK, and others, and applications have been filed in 10 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026. The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About ProtofibrilsProtofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.¹ Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.²About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies cocommercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.References1. Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12: 3451. doi:10.1038/s41467-021-23507-z.2. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More

JOYY Reports 4Q and FY2025 Financial Results: Q4 Revenue Returns to YoY Growth, BIGO Ads Up 61.5% YoY

SINGAPORE, Mar 11, 2026 - (ACN Newswire via SeaPRwire.com) – JOYY Inc. (NASDAQ: JOYY) announced its unaudited financial results for the fourth quarter and full year of 2025.In the fourth quarter of 2025, JOYY’s total revenue was US$581.9 million, up 7.7% quarter over quarter and 5.9% year over year, marking a return to year-over-year revenue growth. Livestreaming revenue was US$394.4 million, up 1.5% quarter over quarter, marking the third consecutive quarter of sequential growth. BIGO Ads delivered accelerating revenue growth, up 61.5% year over year to US$128.1 million. For the full year of 2025, total revenue was US$2.12 billion. Livestreaming contributed US$1.53 billion, while BIGO Ads contributed US$398.5 million, up 38.5% year over year, driving total non-livestreaming revenue, including ad revenue and others, to 28.0% of the Company’s revenue, up 7.9 percentage points from 2024.In 2025, JOYY delivered steady profitability growth. Non-GAAP[1] operating income and non-GAAP[1] EBITDA were US$150.8 million and US$189.8 million, up 10.8% and 10.9% year over year, respectively. In the fourth quarter, non-GAAP1 operating income stood at US$40.8 million, and operating cash flow for the fourth quarter totaled US$116.0 million. As of December 31, 2025, the Company held US$3.26 billion in net cash.JOYY previously announced a shareholder return program of approximately US$900 million through dividends and share repurchases from 2025 through 2027. The Company has been actively executing its share repurchase program, with repurchases totaling US$67.4 million in the fourth quarter. In total, JOYY has distributed approximately US$332.0 million in dividends and share repurchases throughout 2025. In light of the double-digit improvements in operational profit in 2025, the Company will distribute an additional cash dividend of approximately US$20 million in the first quarter of 2026.Fourth Quarter 2025 Financial Highlights- Net revenues increased by 5.9% to US$581.9 million from US$549.4 million in the corresponding period of 2024 and by 7.7% from US$540.2 million in the third quarter of 2025.Livestreaming revenue was US$394.4 million, representing an increase of 1.5% from US$388.5 million in the third quarter of 2025.Advertising revenue increased by 62.4% to US$145.4 million from US$89.6 million in the corresponding period of 2024 and by 29.3% from US$112.5 million in the third quarter of 2025.Other revenues increased by 12.3% to US$42.1 million from US$37.5 million in the corresponding period of 2024 and by 7.2% from US$39.2 million in the third quarter of 2025.- Operating income was US$18.3 million.- Non-GAAP1 operating income was US$40.8 million.- Net Cash as of December 31, 2025 was US$3.26 billion.- Net cash from operating activities was US$116.0 million, compared with US$110.5 million in the corresponding period of 2024.Full Year 2025 Financial Highlights- Net revenues were US$2,124.2 million.- Operating income was US$55.8 million.- Non-GAAP1 operating income was US$150.8 million, up 10.8% from US$136.1 million in 2024.- Non-GAAP1 EBITDA was US$189.8 million, up 10.9% from US$171.2 million in 2024.[1]This press release includes certain non-GAAP financial measures as additional clarifying items to aid investors in further understanding the Company's performance and the impact that these items and events had on the financial results. The non-GAAP financial measures provided above should not be considered as a substitute for, or superior to, the measures of financial performance prepared in accordance with GAAP. For details of the non-GAAP measures, including the reconciliations of GAAP measures to non-GAAP measures, please refer to the press release titled “JOYY Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results” issued by the Company on March 11, 2026. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
HYVE.Promo Launches as APAC’s Newest Print-on-Demand Platform for Corporate Gifting — Powered by AI and Built for Scale SeaPRwire

HYVE.Promo Launches as APAC’s Newest Print-on-Demand Platform for Corporate Gifting — Powered by AI and Built for Scale

Singapore – March 11, 2026 – (SeaPRwire) – HYVE Promo today announced the launch of its AI-enabled print-on-demand platform designed to modernize Asia-Pacific’s corporate gifting and branded merchandise industry. While e-commerce in Asia has produced multi-billion-dollar unicorns, the region’s corporate gifting supply chain remains largely manual — dependent on spreadsheets, fragmented factory coordination, and week-long quote cycles. HYVE enters the market as a technology-first infrastructure platform built to streamline customization, printing, and cross-border fulfillment at scale. HYVE positions itself as the corporate gifting equivalent of Asia’s major e-commerce platforms — purpose-built for businesses that need fast, reliable, and compliant branded merchandise delivered across multiple markets. “Asia built some of the world’s largest e-commerce engines,” said Tim Ngiam, General Manager of HYVE. “But the corporate merchandise industry hasn’t kept pace. We built HYVE to bring platform thinking, AI-driven workflows, and print-on-demand efficiency to a sector still operating like it’s 2005.” AI-Driven Merch Infrastructure HYVE combines: AI-assisted artwork processing and print optimization Real-time production routing across decoration technologies Automated order batching for small and mid-sized runs Cross-border logistics orchestration for APAC distribution The platform integrates directly with HYVE’s high-capacity production hub in Ningbo, China, capable of processing approximately 500 orders daily. Small-batch corporate orders can ship in as little as 72 hours, serving markets including Singapore, Japan, Korea, India, Southeast Asia, and Greater China. Rather than operating as a marketplace aggregator, HYVE controls the full print-to-ship workflow — reducing supplier handoffs and production errors. Targeting a Rapidly Digitizing Market The global promotional products market is projected to reach US$37 billion by 2033, while Asia-Pacific corporate gifting is expected to exceed US$400 billion within the same timeframe. More than 40% of buyers now expect to manage merchandise orders digitally — from proofing to tracking to fulfillment. HYVE aims to become what its founders call “Asia’s largest merch engine” — a centralized infrastructure layer for corporate gifting across the region. “Marketers and procurement teams want the same simplicity they get when ordering consumer products online,” said Ethan Ung, Co-Founder and Chief Commercial Officer. “They don’t want to manage factories, chase quotes, or coordinate customs. They want speed, visibility, and certainty. That’s what a platform should provide.” Built for Enterprise and Regional Scale HYVE focuses initially on APAC enterprise buyers and distributors, offering: On-demand production Regional multi-country fulfillment Compliance-ready manufacturing standards Rapid turnaround for campaign-driven activations The company plans to expand product categories, introduce deeper AI automation across artwork and routing, and integrate with marketing and e-commerce ecosystems used by enterprise teams. About HYVE Promo HYVE Promo is a Singapore-based technology platform modernizing corporate gifting across Asia-Pacific. Backed by the founders of BrandCharger and Headwind Group, HYVE operates a vertically integrated print and fulfillment engine designed to bring AI-driven efficiency, transparency, and scalability to branded merchandise distribution. For more information, visit: https://hyve.promo Media Contact Ming Yi Lim, Marketing Manager HYVE Promo Pte Ltd mingyi.lim@hyve.promo
More
LiTime 推出 LiHeat™:行业首创的低温环境锂电池充电双模式自加热技术 Finance

LiTime 推出 LiHeat™:行业首创的低温环境锂电池充电双模式自加热技术

(SeaPRwire) - 纽约,2026年3月10日 -- 锂电池不喜欢寒冷的环境。当温度降至冰点以下时,大多数锂电池会停止充电,以保护其内部电池单元 —— 这对于在冬季条件下使用房车的车主、离网太阳能用户、户外探险者和冰钓爱好者来说,是一个长期存在的难题。 LiTime是磷酸铁锂(LiFePO4)储能系统领域的创新者,该公司表示已经找到了解决这一限制的方法。 该公司推出了LiHeat™,这是一项获得专利的双模式自加热技术,旨在帮助锂电池更快达到安全充电温度,并在寒冷环境中更可靠地运行。 从被动加热到智能热管理 传统的自加热锂电池设计通常依赖于一种被称为插电加热的单一加热方式,即通过外部充电器为加热元件供电,直到电池达到安全充电温度。 LiHeat™增加了第二种功能:自供电加热。在寒冷环境中,电池可以在连接外部充电器之前,利用自身储存的能量来加热电池单元。因此,一旦连接充电器,就可以立即开始充电,而无需等待电池升温。 该系统还支持自动模式切换。如果仅靠自加热无法使电池达到所需温度,LiHeat™会自动切换到插电加热模式,利用外部电源继续加热电池单元,直到达到安全充电条件。 这两种模式共同将传统的加热方式从被动过程转变为更智能、更灵活的热管理系统 —— 尤其适用于寒冷天气下的锂电池应用。 充电前预热可节省时间和太阳能 通过LiTime蓝牙应用程序,当环境温度高于 -20°C且电池的充电状态高于20%时,用户可以远程激活自加热功能。这使得电池能够提前预热,一旦连接电源即可立即开始充电。 这一功能在冬季太阳能应用中尤为重要。在寒冷的早晨,当太阳能电池板开始发电时,配备LiHeat™的电池能够更快达到可充电状态,有助于确保太阳能被捕获,而不会因温度限制而损失。 扩展至LiTime产品线 LiTime已开始将LiHeat™技术集成到其自加热电池系列的几款锂电池型号中,包括: 12V 100Ah Group24自加热电池12V 165Ah自加热电池12V 320Ah迷你自加热电池24V 230Ah自加热电池 这些产品非常适合寒冷天气下的应用,如冬季房车露营、离网太阳能系统、冰钓设备以及极端条件下的户外探险,能够在低温环境下提供可靠的电力。 该公司表示,计划推出更多具有不同电压和容量选项的LiHeat™电池。所有型号均配备支持蓝牙的电池管理系统(BMS),用户可以通过LiTime应用程序监控温度、调整加热模式和管理电池设置。 随着储能系统越来越多地应用于户外、高纬度和极端气候环境,对适用于寒冷天气的电池的需求持续增长。 LiTime表示,LiHeat™代表了电池热管理领域的一项进步,旨在即使在零下环境中也能提供可靠的充电和稳定的性能。 关于LiTime 为几代人的户外探险提供动力! LiTime作为能源技术探索者,为房车、船舶、太阳能和离网应用提供可靠的磷酸铁锂(LiFePO₄)电力系统 —— 这是一种可规划的能源。在“生活与发现”理念的指引下,LiTime将16年的研发和严格的制造工艺与380多项认证相结合,使锂能源解决方案更智能、更安全、更灵活、更经济实惠 —— 帮助探险者和专业人士借助清洁能源走得更远,从梦想走向规划,再到踏上征程。 了解更多信息公司: LiTime美国/德国/日本网址: https://www.litime.com 联系方式: marketpr@litime.com联系人: Jelly Xie订阅渠道:https://www.facebook.com/litimepower https://www.instagram.com/litimepower/ https://www.youtube.com/@litimepower 随本公告发布的照片可在以下网址查看: https://www.globenewswire.com/NewsRoom/AttachmentNg/24e68d4f-ce8f-47eb-ab55-a159f5873649 https://www.globenewswire.com/NewsRoom/AttachmentNg/b9a6ef7c-c7a3-4d2b-a54c-bf3fd44f8e02本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More